Loss of PBRM1 expression is associated with renal cell carcinoma progression

International Journal of Cancer

Volumn 132, Issue 2, 2013, Pages

  Pawłowski, Rafal ^a   Mühl, Sarah M ^a   Sulser, Tullio ^b   Krek, Wilhelm ^a   Moch, Holger ^b   Schraml, Peter ^b  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

BAF180; PBRM1; renal cell cancer; VHL

Indexed keywords

POLYBROMO 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER THERAPY; CHROMATIN; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LOSS OF FUNCTION MUTATION; OUTCOME ASSESSMENT; PBRM1 GENE; PRIORITY JOURNAL;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MUTATION; NEOPLASM STAGING; NUCLEAR PROTEINS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84869487977     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27822     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-65.
3. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon-α in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90.
4. Schlesinger-Raab A, Treiber U, Zaak D, et al. Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up. Eur J Cancer 2008; 44: 2485-95.
5. Allory Y, Culine S, de la Taille A,. Kidney cancer pathology in the new context of targeted therapy. Pathobiology 2011; 78: 90-8.
6. Eble JN, Sauter G, Epstein JI, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004.
7. Banks RE, Tirukonda P, Taylor C, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006; 66: 2000-11.
8. Cowey CL, Rathmell WK,. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009; 11: 94-101.
9. Gossage L, Eisen T,. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010; 7: 277-88.
10. Rechsteiner MP, von Teichman A, Nowicka A, et al. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. Cancer Res 2011; 71: 5500-11.
11. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer 2005; 5: 57.
12. Amin MB, MacLennan GT, Gupta R, et al. Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol 2009; 33: 384-92.
13. Vickers MM, Heng DY,. Prognostic and predictive biomarkers in renal cell carcinoma. Target Oncol 2010; 5: 85-94.
14. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360-3.
15. Duns G, Hofstra RM, Sietzema JG, et al. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat 2012; 33: 1059-62.
16. van Haaften G, Dalgliesh GL, Davies H, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41: 521-3.
17. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-42.
18. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44: 751-9.
19. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
20. Burrows AE, Smogorzewska A, Elledge SJ,. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci USA 2010; 107: 14280-5.
21. Hergovich A, Lisztwan J, Barry R, et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003; 5: 64-70.
22. Hergovich A, Lisztwan J, Thoma CR, et al. Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Mol Cell Biol 2006; 26: 5784-96.
23. Thoma CR, Frew IJ, Hoerner CR, et al. pVHL and GSK3β are components of a primary cilium-maintenance signalling network. Nat Cell Biol 2007; 9: 588-95.
24. Struckmann K, Mertz K, Steu S, et al. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol 2008; 214: 464-71.
25. Dahinden C, Ingold B, Wild P, et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 2010; 16: 88-98.
26. Mertz KD, Demichelis F, Kim R, et al. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol 2007; 38: 1454-62.
27. Djouder N, Metzler SC, Schmidt A, et al. S6K1-mediated disassembly of mitochondrial URI/PP1γ complexes activates a negative feedback program that counters S6K1 survival signaling. Mol Cell 2007; 28: 28-40.
28. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-4.
29. Baldewijns MM, van Vlodrop IJ, Schouten LJ, et al. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 2008; 1785: 133-55.
30. Zabarovsky ER, Lerman MI, Minna JD,. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002; 21: 6915-35.
31. Frew IJ, Minola A, Georgiev S, et al. Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. Mol Cell Biol 2008; 28: 4536-48.
32. Frew IJ, Thoma CR, Georgiev S, et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 2008; 27: 1747-57.
33. Iliopoulos O, Kibel A, Gray S, et al. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995; 1: 822-6.
34. Thoma CR, Toso A, Gutbrodt KL, et al. VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 2009; 11: 994-1001.